Video

Case Study: Importance of Iron Chelation Therapy in MDS

For High-Definition, Click

Azra Raza, MD, has been dedicated to treating and researching myelodysplastic syndrome (MDS) for over 30 years. In an average week, Raza treats approximately 50 patients with MDS, which has led to an in-depth understanding of the chronic morbidities associated with this disease, including iron overload.

As an example of the importance of iron chelation therapy (ICT), Raza describes a male patient with low-risk MDS in his late 60s who developed signs of chronic iron overload following treatment. However, the patient was resistant to receiving ICT, which resulted in his hospitalization for acute heart failure.

A T2* MRI showed immense iron overload with a ferritin level greater than 7000 µg/g, which required aggressive ICT. After nearly 2 months of treatment, the patient was released from the hospital. This case study demonstrates the dangers associated with not managing iron levels, Raza suggests.

Related Videos
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.